This HTML5 document contains 15 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Subject Item

n2:w

rdf:type

rdac:C10001 bibo:Article

dcterms:isPartOf

n8:w

dcterms:subject

n13:reports

dcterms:title

Pharmacokinetics and Mechanism of Action of a Doxorubicin-Monoclonal Antibody 9.2.27 Conjugate Directed to a Human Melanoma Proteoglycan

rdaw:P10072

n15:print n15:web

vivo:relatedBy

n11:1 n11:2

marcrel:aut

n2:reisfeldralpha n2:yanghming

dcterms:abstract

Doxorubicin (DXR) conjugated to a monoclonal antibody (MAb), 9.2.27, which recognizes a human melanoma-associated proteoglycan, effectively suppresses the growth of human melanoma xenografts and prolongs the life span of tumor-bearing athymic nude (nulnu) mice. We have investigated further the mechanism(s) of this in viva antitu-mor activity. Our results indicate that following iv injection, the DXR-MAb 9.2.27 conjugate is cleared from the circulation with typical Diphasic kinetics, similar to the clearance process of the unconjugated MAb 9.2.27. In contrast, less than 10% of injected dose per milliliter of blood is found in the circulation at any given time after ip injection. Toxicity studies further indicate that DXR-MAb 9.2.27 conjugate is less toxic in vivo than the freely administered DXR, which is known to cause considerable cardiotoxic effects. Direct autoradiography demonstrates that the DXR-MAb 9.2.27 conjugate binds specifically to the tissue sections derived from a human melanoma xenograft of a nude mouse. A critical evaluation is given of the relevance of these findings and their impact on the design of future strategies for the immunochemotherapy of malignant melanoma. [J Natl Cancer Inst 1988;80:l154-1159]

hub:articleType

n4:other

hub:publisher-id

80.14.1154

hub:isPartOfThisJournal

n9:w